Old Web
English
Sign In
Acemap
>
authorDetail
>
Karen McDougall
Karen McDougall
Imatinib
Medicine
Immunology
Median follow-up
Adverse effect
4
Papers
793
Citations
0.01
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (4)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
High-Dose Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia: High Rates of Rapid Cytogenetic and Molecular Responses
2009
Journal of Clinical Oncology
Jorge E. Cortes
Hagop M. Kantarjian
Stuart L. Goldberg
Bayard L. Powell
Francis J. Giles
Meir Wetzler
Luke P. Akard
John M. Burke
Robert Kerr
Mansoor N. Saleh
August J. Salvado
Karen McDougall
Maher Albitar
Jerald P. Radich
Show All
Source
Cite
Save
Citations (113)
Molecular Responses in Newly Diagnosed Chronic Myelocytic Leukemia (CML) Patients Treated with 800 mg Imatinib Daily: An Update from the RIGHT Trial Study Group.
2006
Blood
Jorge E. Cortes
Francis J. Giles
August J. Salvado
Karen McDougall
Jerald P. Radich
Maher Albitar
Bayard L. Powell
Stuart L. Goldberg
Hagop M. Kantarjian
Show All
Source
Cite
Save
Citations (13)
Molecular Correlates of Imatinib Resistance in Gastrointestinal Stromal Tumors
2006
Journal of Clinical Oncology
Michael Heinrich
Christopher L. Corless
Charles D. Blanke
George D. Demetri
Heikki Joensuu
Peter J. Roberts
Burton L. Eisenberg
Margaret von Mehren
Christopher D. M. Fletcher
Katrin Sandau
Karen McDougall
Wen-Bin Ou
Chang Jie Chen
Jonathan A. Fletcher
Show All
Source
Cite
Save
Citations (664)
Interim Analysis of a Multicenter Trial of High Dose (HD) Imatinib in Newly Diagnosed Early Chronic Phase (CP) Patients (pt) with Chronic Myeloid Leukemia (CML).
2005
Blood
Jorge E. Cortes
Francis J. Giles
August J. Salvado
Karen McDougall
Jerald P. Radich
Mahir Albitar
Bayard L. Powell
Stuart L. Goldberg
Hagop M. Kantarjian
Show All
Source
Cite
Save
Citations (3)
1